Journal
ACTA NEUROLOGICA BELGICA
Volume 121, Issue 4, Pages 949-954Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13760-020-01477-1
Keywords
Alzheimer's disease; Disease severity; Galactin-3; Microglial activation; Neurodegeneration; Neuroinflammation
Categories
Ask authors/readers for more resources
This study found that serum galectin-3 levels were significantly higher in patients with Alzheimer's disease compared to healthy controls, while other parameters showed no significant differences between the groups. Additionally, it was observed that serum galectin-3 levels, patient age, and disease duration all significantly increased with the stage of the disease in all Alzheimer's disease patients.
Background and Aims Neuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer's disease (AD). Methods This was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls. Results In our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience's age, and duration of disease were statically and significantly increased (p < 0.05). Conclusion In conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available